NCT03492918
Breast Cancer Type: HER2+, HR+ & HER2-negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Not yet recruiting
Phase 2
Drug Category: Immunotherapy, Therapeutic Antibody

Key Eligibility Criteria:

Gender: Female
Age: 19 Years and older (Adult), Senior)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with known active central nervous system (CNS) metastases- see trial for details
https://ClinicalTrials.gov/show/NCT03492918